rss
Ann Rheum Dis 2009;68:508-513 doi:10.1136/ard.2008.087833
  • Clinical and epidemiological research

Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study

  1. I Hafström1,
  2. K Albertsson1,
  3. A Boonen2,
  4. D van der Heijde3,
  5. R Landewé4,
  6. B Svensson5,
  7. for the BARFOT Study Group
  1. 1
    The Rheumatology Unit, Karolinska Institute, Karolinska University Hospital, Huddinge, Stockholm, Sweden
  2. 2
    Department of Internal Medicine, Division of Rheumatology, University Hospital, and CAPHRI Research Institute, Maastricht, The Netherlands
  3. 3
    Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
  4. 4
    Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, and CAPHRI Research Institute, Maastricht, The Netherlands
  5. 5
    Department of Rheumatology, Lund University, Lund, Sweden
  1. Ingiäld Hafström, Rheumatology Department, R92, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden; ingiald.hafstrom{at}karolinska.se
  • Accepted 9 April 2008
  • Published Online First 17 April 2008

Abstract

Objective: To evaluate if remission induced by low-dose prednisolone during the first 2 years of rheumatoid arthritis (RA) in the BARFOT glucocorticoid (GC) study had a sustained effect on radiological damage for a total of 4 years.

Methods: A total of 150 of 211 eligible patients with RA who had been randomised to the 7.5 mg prednisolone group (P) or no prednisolone group (NoP) in addition to the initial disease-modifying antirheumatic drugs were included. Radiographs of hands and feet were scored using the Sharp–van der Heijde scoring method. A patient was considered to be in remission if the 28-joint count disease activity score was <2.6.

Results: Mean (SD) age was 53 (14) and 57 (12) years for the patients in the P and NoP groups, respectively. 64% were female, 64% rheumatoid factor positive, and disease duration at baseline was 6 months. At 2 years the proportion of patients in remission in the P and NoP groups was 55 vs 30%, p = 0.003. Longitudinal analysis showed that over the entire course of the disease, patients on prednisolone had a higher probability of being in remission. Patients in remission at 2 years, compared with those not in remission, had significantly lower total Sharp score, erosion score and joint space narrowing score at 2 and 4 years. The changes in bone mineral density during the 4 years did not differ between those in remission and those with active disease, and were similar in the two treatment groups.

Conclusions: Prednisolone 7.5 mg daily in addition to disease-modifying anti-rheumatic drugs increases the rate of remission in patients with early RA, which has a beneficial and sustained effect on radiological damage.

Footnotes

  • Competing interests: None.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. ard.2008.087833v1
    2. 68/4/508 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.